Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid
Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid
复制标题
磺胺甲氧基哒嗪治疗疱疹样皮炎、线性 IgA 疾病和疤痕性类天疱疮
DOI：
--
复制
发表时间：
1989
影响因子：
10.3
通讯作者：
L. Fry
中科院分区：
文献类型：
--
作者：
J. McFadden;J. Leonard;A. Powles;A. Rutman;L. Fry
本文回顾分析了168例疱疹样皮炎患者，比较氨苯砜和磺胺甲氧基吡嗪的临床疗效和不良反应发生率。37例接受磺胺甲氧基吡嗪(0·25~1·5g/d)单药治疗，161例单用氨苯砜(50~450 mg/d)。其中30名患者同时接受了两种药物治疗，但时间不同。氨苯松组有效率为97%，磺胺甲氧基吡嗪组有效率为%。36名(22%)接受氨苯砜治疗的受试者出现了无法忍受的副作用，需要改变治疗方案，而在接受磺胺甲氧基吡嗪治疗的受试者中，只有5名患者(13.5%)出现了这种副作用。磺胺甲氧基吡嗪对3例氨苯砜不良反应的线性IgA病患者和15例口腔和皮肤瘢痕性类天疱疮患者中的10例有效。
One‐hundred and sixty‐eight cases of dermatitis herpetiformis were reviewed to compare the clinical response to and incidence of side‐effects from dapsone and sulphamethoxypyridazine. Thirty‐seven received sulphamethoxypyridazine (0·25–1·5 g/day) as a single agent therapy at some stage during their care and 161 had dapsone only (50–450 mg/day). Thirty of these patients received both drugs, but at different times. Both were highly effective in controlling the skin disease in 97% of patients on dapsone and 89% on sulphamethoxypyridazine. While 36 (22%) of dapsone‐treated subjects had intolerable side effects warranting a change in therapy, this occurred in only five (13·5%) of those treated with sulphamethoxypyridazine. Sulphamethoxypyridazine was also effective as a single agent in three patients with linear IgA disease who had suffered adverse effects from dapsone, and in 10 out of 15 patients with oral and cutaneous lesions of cicatricial pemphigoid.